Jose Biju, Tahrani Abd A, Piya Milan K, Barnett Anthony H
Department of Diabetes and Endocrinology, Heart of England NHS Foundation Trust, Birmingham, UK;
Patient Prefer Adherence. 2010 Sep 7;4:313-24. doi: 10.2147/ppa.s7494.
Type 2 diabetes mellitus (T2DM) is a complex disorder in which interactions between environmental and genetic factors result in the development of insulin resistance (in most cases) and progressive pancreatic β-cell failure. The currently available oral anti-diabetes treatments are effective as monotherapy; however, due to the progressive decline in β-cell function, most patients will require the use of combination therapy and eventually insulin to reach glycemic targets. These therapeutic options are not without undesirable side effects such as weight gain and hypoglycemia. Furthermore, T2DM is associated with impaired quality of life (QOL) and poor compliance with treatment. Hence, there is a need for anti-diabetes agents that result in sustained improvements in glycemic control without hypoglycemia or weight gain and have a positive impact on patients QOL and thereby hopefully improve compliance. Incretin-based therapy is the latest addition to anti-diabetes treatments which addresses some of the shortcomings of older treatments.
To review the evidence for the use of exenatide once-weekly.
We have searched Medline using the terms "exenatide", "exenatide once-weekly", and "exenatide LA".
Exenatide once-weekly is an incretin mimetic that is currently undergoing phase 3 clinical trials, and has been shown to improve glycemic parameters (HbA(1c) and fasting and postprandial glucose levels), with low risk of hypoglycemia, causes weight loss, and use was associated with improvements in patient satisfaction which might have a positive impact on treatment compliance.
Exenatide once-weekly is effective, well tolerated in patients with T2DM and should be a useful addition to the available range of anti-diabetes treatments.
2型糖尿病（T2DM）是一种复杂的疾病，环境因素与遗传因素相互作用导致胰岛素抵抗（大多数情况下）以及胰腺β细胞功能进行性衰竭。目前可用的口服抗糖尿病药物作为单一疗法是有效的；然而，由于β细胞功能的逐渐下降，大多数患者将需要使用联合疗法并最终使用胰岛素来达到血糖目标。这些治疗选择并非没有不良副作用，如体重增加和低血糖。此外，T2DM与生活质量（QOL）受损和治疗依从性差有关。因此，需要一种抗糖尿病药物，能在不引起低血糖或体重增加的情况下持续改善血糖控制，并对患者的生活质量产生积极影响，从而有望提高依从性。基于肠促胰素的疗法是抗糖尿病治疗的最新补充，解决了一些传统疗法的缺点。
综述每周一次使用艾塞那肽的证据。
我们使用“艾塞那肽”、“每周一次艾塞那肽”和“长效艾塞那肽”等术语检索了Medline。
每周一次艾塞那肽是一种肠促胰素类似物，目前正在进行3期临床试验，已显示可改善血糖参数（糖化血红蛋白（HbA1c）以及空腹和餐后血糖水平），低血糖风险低，可导致体重减轻，使用该药物与患者满意度提高相关，这可能对治疗依从性产生积极影响。
每周一次艾塞那肽有效，T2DM患者耐受性良好，应成为现有抗糖尿病治疗药物中的有益补充。
